Patent · US Active

Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domains

US11618776B2 · kind B2 · utility

1Cited by

46References

7Claims

0Family size

Assignee

Xencor, Inc. · US

Inventors

Matthew Bernett · Monrovia, US
John Desjarlais · Pasadena, US
Rajat Varma · Hamden, US
Gregory Moore · Monrovia, US
Juan Diaz · Cerro Villa Heights, US
Alex Nisthal · Monrovia, US
Ke Liu · Hanover, US
Rumana Rashid · Temple City, US
Eric Chang · Walnut, US

Key dates

Filing date	Dec 20, 2019
Grant date	Apr 4, 2023
Priority date	—
Expiry date	Jan 25, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/32
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to a novel targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc fusion protein and an NKG2D antigen binding domain Fc fusion proteins.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.